com
1
ANY OF YOU
YOU
VC VC
Biotech
2
The Evolution of the Drug Discovery
Landscape in 2011
3
The Evolution of the Drug Discovery
Landscape in 2011
Biotechs
§ SBIR Grants
§ NIH Grants
§ Non-Profits
§ VC Funding
§ Strategic Alliances
§ Regional marketing licenses
§ M&A
§ IPO
4
AMRI Global Integrated Drug Discovery,
Development & Manufacturing Services
As a global leader in drug discovery, AMRI provides valuable contract discovery,
development, and manufacturing services to advance our clients goals.
5
Key AMRI Distinctions
• 72
pre-clinical and clinical
candidates
• 90
Issued US Patents
(dozens additional filings)
175 Drug Discovery
Programs • 300
Peer reviewed
publications
• 400
Verbal Presentations and
Posters
31 CNS Programs • 19
pre-clinical and clinical
candidates
16 Antibacterial Programs • 6
pre-clinical and clinical
candidates
30 Oncology Programs • 12
pre-clinical and clinical
candidates
9
Biology Therapeutic and
Target Class Distinction
Natural Products
Fragments
Diverse Screening Sets
In Vivo Relationships
10
Strong R&D Pipeline
11
Announced Integrated Programs
Therapeutic
Area Leaders
(TAL)
Established
in Vitro Biology
Chemistry Lead ADMET Lead in Vivo
Lead
Providers
Efficacy PK/Tox
13
Established in Vivo Partners
14
East Meets West
Quality Cost
Hybrid
Model
Computational Chemistry
Activity Property
Optimization
SAR SPR
Redesign
Hit Generation
• Screening based approach: structure-based drug design/virtual library screening, AMRI
compound libraries, open access libraries, custom library synthesis
• Fast follower/scaffold-hopping approach
Lead Generation
• Hit-to-Lead optimization - iterative parallel optimization of SAR & SPR
• Establish proprietary chemotypes with best potential to advance to lead opt stage
• Parallel / traditional synthesis
• Evidence of in vivo activity – Proof of concept study
Lead Optimization
• Thorough SAR and SPR optimization
• Optimize in vivo PK/PD, minimize off-target activity, minimize Tox liabilities progress
compounds that meet preclinical candidate selection criteria
Creation & Protection of
Customer s Intellectual Property
Facilities Overview
• >450 fume hoods
• Modern synthetic technologies
• Parallel synthesis and purification
• Focused Library Synthesis
• Full analytical support staff and facilities
• State-of-the-art library and search tools
• CADD and database support
Computer-Aided Drug Discovery
• Virtual Screening
• 2D
• Pharmacophore Searching
• Structure-Based VS
• Homology Modeling
A B
Matthew.reabold@amriglobal.com
Introduction to AMRI IVB
• Key scientists derived from large Pharma, Biotech & local academic
institutions (Pharmacia, J&J, AZ, Icos, Arris, Sugen, Ceptyr)
Reagent Assay
HTS SAR Candidates
production development
95000
Fluorescence
• Fully automated screening 65000
55000
45000
Cell proliferation & cytotoxicity 3H-Thymidine uptake / Alamar Blue / MTT / MTS / CellTiter-Glo® / ApoGlow®
Questions???
mattthew.reabold@amriglobal.com